Edwards Lifesciences Corp (EW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 823,400 | 1,046,900 | 722,200 | 583,600 | 569,500 |
| Depreciation Amortization | 107,200 | 89,300 | 77,400 | 81,900 | 71,200 |
| Income taxes - deferred | -49,400 | 12,100 | -27,300 | 17,800 | -37,400 |
| Accounts receivable | 41,900 | -88,000 | -28,700 | -27,800 | -60,400 |
| Other Working Capital | -228,300 | 3,200 | -222,700 | 240,900 | 99,500 |
| Other Operating Activity | 359,500 | 119,400 | 405,800 | 104,300 | 62,000 |
| Operating Cash Flow | $1,054,300 | $1,182,900 | $926,700 | $1,000,700 | $704,400 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | N/A | N/A | N/A | -9,800 |
| PPE Investments | -407,000 | -254,400 | -238,700 | -168,100 | -176,100 |
| Net Acquisitions | -10,000 | -135,200 | N/A | -192,900 | N/A |
| Purchase Of Investment | -851,700 | -568,100 | -459,300 | -1,334,700 | -1,072,700 |
| Sale Of Investment | 777,000 | 409,900 | 801,300 | 1,103,400 | 1,087,000 |
| Purchase Sale Intangibles | -300 | -24,000 | -3,000 | -7,400 | -41,300 |
| Other Investing Activity | -39,400 | -48,000 | -26,600 | -54,900 | -40,100 |
| Investing Cash Flow | $-531,100 | $-595,800 | $76,700 | $-647,200 | $-211,700 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 16,200 | 18,900 | 688,000 | 994,700 | 253,500 |
| Debt Repayment | -17,000 | -28,900 | -1,125,300 | -818,400 | -31,400 |
| Common Stock Issued | 140,500 | 160,500 | 147,000 | 113,800 | 103,300 |
| Common Stock Repurchased | -625,400 | -263,300 | -795,500 | -763,300 | -662,300 |
| Other Financing Activity | -1,200 | -2,800 | -15,400 | 0 | 68,400 |
| Financing Cash Flow | $-486,900 | $-115,600 | $-1,101,200 | $-473,200 | $-268,500 |
| Exchange Rate Effect | -20,500 | -3,000 | -6,500 | 7,900 | -12,500 |
| Beginning Cash Position | 1,184,400 | 715,900 | 820,200 | 930,100 | 718,400 |
| End Cash Position | 1,200,200 | 1,184,400 | 715,900 | 818,300 | 930,100 |
| Net Cash Flow | $15,800 | $468,500 | $-104,300 | $-111,800 | $211,700 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,054,300 | 1,182,900 | 926,700 | 1,000,700 | 704,400 |
| Capital Expenditure | -407,000 | -254,400 | -238,700 | -168,100 | -176,100 |
| Free Cash Flow | 647,300 | 928,500 | 688,000 | 832,600 | 528,300 |